Finding Immune Nascent Type 1 Diabetes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-99
SponsorIndiana University
About this trial
The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:
What form of recruitment communication is most effective for completing a type 1diabetes home screening kit?
Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).
Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.
Eligibility criteria
Qualifiers
Participant must be in Indiana Biobank
Participant must be able to provide consent
Ages 1-99 including pregnant women
Disqualifiers
Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study
While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening
Trial design
Treatments tested in this trial
- phone call
- email/mail
Treatment groups
3,800 Participants
are divided into 2 treatment groupsSponsors and collaborators
Indiana University
Lead sponsor
Sanofi
Collaborator
Source ClinicalTrials.gov